Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Logistic regression analysis showed that occurrence of vertebral fractures, considered as dependent variable, was not predicted by age, serum 25OHD and urine PEA levels, neck T-score, hypercalciuria/kidney stones and familiarity for fragility fractures, considered as independent variables.Anthropometric, biochemical, hormone and DXA-derived parameters: comparison between patients harboring pathogenic, benign variants and the wild-type alleles of the ALPL geneParametersPathogenic ALPL variantsBenign ALPL variantsWild-type ALPL allelesPAge (years)58.8 ± 3.359.1 ± 4.553.4 ± 3.80.535BMI (kg/m2)25.8 ± 0.921.7 ± 1.823.7 ± 2.10.453Serum total ALP (U/L)26.1 ± 2.332.3 ± 2.530.8 ± 2.30.274Serum CTX (ng/mL)0.541 ± 0.0880.482 ± 0.0810.285 ± 0.0540.051Serum total calcium (mg/dL)9.2 ± 0.29.3 ± 0.19.4 ± 0.10.723Serum phosphate (mg/dL)3.8 ± 0.23.4 ± 0.23.3 ± 0.20.237Serum 25OHD (ng/mL)29.6 ± 5.239.0 ± 3.342.8 ± 3.80.112Serum 25OHD < 30 ng/mL, n (%)3 (60%)1 (12.5%)1 (11%)0.080Plasma PTH (pg/mL)55.3 ± 8.041.2 ± 8.556.3 ± 7.80.205UCa (mg/24 h)186.4 ± 25.5212.3 ± 21.8154.4 ± 11.00.101UCa (mg/kg/24 h)2.7 ± 0.33.8 ± 0.52.6 ± 0.20.048L1-L4 T-score− 1.96 ± 0.74− 1.94 ± 0.78− 1.54 ± 0.370.849Femoral neck T-score− 2.14 ± 0.38− 1.88 ± 0.27− 1.50 ± 0.360.453Total hip T-score− 1.33 ± 0.59− 1.41 ± 0.29− 1.27 ± 0.300.950DXA osteoporosis, n (%)2 (40%)4 (50%)4 (44%)0.937Urinary PEA(mmol/mol creatinine)5.8 ± 0.33.1 ± 0.72.3 ± 0.60.005Serum PLP (µg/L)30.5 ± 13.611.0 ± 0.910.6 ± 2.00.050Data are presented as mean ± SEM and compared by oneway-ANOVA corrected by Holm-Sidak test for multiple comparisons.
Source: Clinical features in hypophosphatasemic patients according the ALPL genotype. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This is a single-center cross sectional study, retrospectively enrolling 22 adults with unexplained persistent hypophosphatasemia.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Clinical, biochemical and genetic findings in adult patients with chronic hypophosphatasemia
Cross-sectional study · Journal of Endocrinological Investigation · 2021
Original publication title
Clinical, biochemical and genetic findings in adult patients with chronic hypophosphatasemia
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The study aimed to define the clinical, biochemical and genetic features of adult patients with osteopenia/osteoporosis and/or bone fragility and low serum alkaline phosphatase (sALP).
Source: PurposeAbstract: What methods does the paper describe?
Twenty-two patients with at least two sALP values below the reference range were retrospectively enrolled after exclusion of secondary causes. Data about clinical features, mineral and bone markers, serum pyridoxal-5’-phosphate (PLP), urine phosphoethanolamine (PEA), lumbar and femur bone densitometry, and column X-ray were collected. Peripheral blood DNA of each participant was analyzed to detect ALPL gene anomalies.
Source: MethodsAbstract: Results
Pathogenic ALPL variants (pALPL) occurred in 23% and benign variants in 36% of patients (bALPL), while nine patients harbored wild-type alleles (wtALPL). Fragility fractures and dental anomalies were more frequent in patients harboring pALPL and bALPL than in wtALPL patients. Of note, wtALPL patients comprised women treated with tamoxifen for hormone-sensitive breast cancer. Mineral and bone markers were similar in the three groups. Mean urine PEA levels were significantly higher in patients harboring pALPL than those detected in patients harboring bALPL and wtALPL; by contrast, serum PLP levels were similar in the three groups.
A 6-points score, considering clinical and biochemical features, was predictive of pALPL detection [P = 0.060, OR 1.92 (95% CI 0.972, 3.794)], and more significantly of pALPL or bALPL [P = 0.025, OR 14.33 (95% CI 1.401, 14.605)].
Source: ResultsAbstract: Conclusion
In osteopenic/osteoporotic patients, single clinical or biochemical factors did not distinguish hypophosphatasemic patients harboring pALPL or bALPL from those harboring wtALPL. Occurrence of multiple clinical and biochemical features is predictive of ALPL anomalies, and, therefore, they should be carefully identified. Tamoxifen emerged as a hypophosphatasemic drug.
Source: ConclusionAuthors’ abstract
Purpose
The study aimed to define the clinical, biochemical and genetic features of adult patients with osteopenia/osteoporosis and/or bone fragility and low serum alkaline phosphatase (sALP).
Methods
Twenty-two patients with at least two sALP values below the reference range were retrospectively enrolled after exclusion of secondary causes. Data about clinical features, mineral and bone markers, serum pyridoxal-5’-phosphate (PLP), urine phosphoethanolamine (PEA), lumbar and femur bone densitometry, and column X-ray were collected. Peripheral blood DNA of each participant was analyzed to detect ALPL gene anomalies.
Results
Pathogenic ALPL variants (pALPL) occurred in 23% and benign variants in 36% of patients (bALPL), while nine patients harbored wild-type alleles (wtALPL). Fragility fractures and dental anomalies were more frequent in patients harboring pALPL and bALPL than in wtALPL patients. Of note, wtALPL patients comprised women treated with tamoxifen for hormone-sensitive breast cancer. Mineral and bone markers were similar in the three groups. Mean urine PEA levels were significantly higher in patients harboring pALPL than those detected in patients harboring bALPL and wtALPL; by contrast, serum PLP levels were similar in the three groups.
A 6-points score, considering clinical and biochemical features, was predictive of pALPL detection [P = 0.060, OR 1.92 (95% CI 0.972, 3.794)], and more significantly of pALPL or bALPL [P = 0.025, OR 14.33 (95% CI 1.401, 14.605)].
Conclusion
In osteopenic/osteoporotic patients, single clinical or biochemical factors did not distinguish hypophosphatasemic patients harboring pALPL or bALPL from those harboring wtALPL. Occurrence of multiple clinical and biochemical features is predictive of ALPL anomalies, and, therefore, they should be carefully identified. Tamoxifen emerged as a hypophosphatasemic drug.
Publication and source details
Original title: Clinical, biochemical and genetic findings in adult patients with chronic hypophosphatasemia
V. Guarnieri; F. Sileri; R. Indirli; G. Guabello; M. Longhi; G. Dito; C. Verdelli; S. Corbetta
Journal of Endocrinological Investigation · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Italian Ministry of HealthGruppo San Donato Foundation5x1000 OsteoregistryCorbetta S. Università degli Studi di MilanoOpen access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T12:12:38.345479+00:00
DOI: 10.1007/s40618-021-01625-1 · PMC8741696